PHILADELPHIA – A drug company may have violated the privacy of thousands of people who are taking a medicine to prevent them from coming down with HIV.
Gilead Sciences, the biopharmaceutical giant, sent out a mass mailing in mid-April to people on its antiretroviral drugs, Truvada and Descovy. The drugs are used to reduce the risk of HIV infection, a prevention measure called pre-exposure prophylaxis (PrEP).
On Thursday, the AIDS Law Project of Pennsylvania filed a federal class action suit against Gilead. It claims the company illegally compromised the privacy rights of patients by recklessly mailing the inappropriately marked envelopes after promising confidentiality.
The suit demands that Gilead’s HIV Prevention Team immediately stop sending out letters to patients and seeks unspecified monetary damages. It was filed in the Northern District of California. The AIDS Law Project was joined by law firms Berger and Montague and Langer Grogan and Diver.
“We regret that the envelope caused any concerns, and we apologize to anyone affected,” Gilead, which is on the forefront of developing a COVID-19 vaccine, said a statement. “However, we deny the assertions in the complaint and will file our response in a timely manner.”
